STOCK TITAN

[Form 4] Tharimmune, Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Form 4 filing reveals that Sanam Parikh, Director of Tharimmune (THAR), executed a direct purchase of company shares on June 20, 2025. The insider transaction details:

  • Acquired 1,000 shares of Common Stock at $1.45 per share
  • Total transaction value: $1,450
  • Following the purchase, Parikh now holds 1,770 shares directly

This insider buying activity by a board member could signal confidence in the company's future prospects. The transaction was reported within the required filing window, with the Form 4 being signed on June 23, 2025. No derivative securities were involved in this transaction.

Il modulo 4 evidenzia che Sanam Parikh, Direttore di Tharimmune (THAR), ha effettuato un acquisto diretto di azioni della società il 20 giugno 2025. Dettagli della transazione interna:

  • Acquisto di 1.000 azioni di Azioni Ordinarie a 1,45 $ per azione
  • Valore totale della transazione: 1.450 $
  • Dopo l'acquisto, Parikh detiene ora direttamente 1.770 azioni

Questa attività di acquisto da parte di un membro del consiglio potrebbe indicare fiducia nelle prospettive future dell'azienda. La transazione è stata segnalata entro la finestra di deposito richiesta, con il modulo 4 firmato il 23 giugno 2025. Non sono stati coinvolti titoli derivati in questa operazione.

La presentación del Formulario 4 revela que Sanam Parikh, Directora de Tharimmune (THAR), realizó una compra directa de acciones de la empresa el 20 de junio de 2025. Detalles de la transacción interna:

  • Adquirió 1,000 acciones de acciones comunes a $1.45 por acción
  • Valor total de la transacción: $1,450
  • Tras la compra, Parikh posee ahora directamente 1,770 acciones

Esta compra por parte de un miembro del consejo podría indicar confianza en las perspectivas futuras de la compañía. La transacción se reportó dentro del plazo requerido, con el Formulario 4 firmado el 23 de junio de 2025. No se involucraron valores derivados en esta operación.

Form 4 제출서에 따르면, Sanam Parikh Tharimmune(THAR) 이사가 2025년 6월 20일 회사 주식을 직접 매수한 것으로 나타났습니다. 내부자 거래 세부 사항은 다음과 같습니다:

  • 1,000주의 보통주를 주당 $1.45에 매수
  • 총 거래 금액: $1,450
  • 매수 후 Parikh 이사는 직접 1,770주를 보유하게 됨

이사회 구성원의 이러한 내부자 매수 활동은 회사의 미래 전망에 대한 신뢰를 나타낼 수 있습니다. 거래는 제출 기한 내에 보고되었으며, Form 4는 2025년 6월 23일에 서명되었습니다. 이 거래에는 파생 증권이 포함되지 않았습니다.

Le dépôt du formulaire 4 révèle que Sanam Parikh, directrice de Tharimmune (THAR), a effectué un achat direct d’actions de la société le 20 juin 2025. Détails de la transaction d’initié :

  • Acheté 1 000 actions ordinaires à 1,45 $ par action
  • Valeur totale de la transaction : 1 450 $
  • Après cet achat, Parikh détient désormais directement 1 770 actions

Cette opération d’achat par un membre du conseil d’administration pourrait indiquer une confiance dans les perspectives futures de l’entreprise. La transaction a été déclarée dans le délai requis, le formulaire 4 ayant été signé le 23 juin 2025. Aucun titre dérivé n’a été impliqué dans cette opération.

Die Einreichung des Formulars 4 zeigt, dass Sanam Parikh, Direktorin von Tharimmune (THAR), am 20. Juni 2025 einen direkten Kauf von Unternehmensaktien getätigt hat. Details der Insider-Transaktion:

  • Erworben wurden 1.000 Stammaktien zu 1,45 $ pro Aktie
  • Gesamtwert der Transaktion: 1.450 $
  • Nach dem Kauf hält Parikh nun direkt 1.770 Aktien

Diese Insider-Kaufaktivität eines Vorstandsmitglieds könnte auf Vertrauen in die zukünftigen Aussichten des Unternehmens hinweisen. Die Transaktion wurde innerhalb des vorgeschriebenen Meldefensters gemeldet, das Formular 4 wurde am 23. Juni 2025 unterzeichnet. Es waren keine Derivate an dieser Transaktion beteiligt.

Positive
  • None.
Negative
  • None.

Il modulo 4 evidenzia che Sanam Parikh, Direttore di Tharimmune (THAR), ha effettuato un acquisto diretto di azioni della società il 20 giugno 2025. Dettagli della transazione interna:

  • Acquisto di 1.000 azioni di Azioni Ordinarie a 1,45 $ per azione
  • Valore totale della transazione: 1.450 $
  • Dopo l'acquisto, Parikh detiene ora direttamente 1.770 azioni

Questa attività di acquisto da parte di un membro del consiglio potrebbe indicare fiducia nelle prospettive future dell'azienda. La transazione è stata segnalata entro la finestra di deposito richiesta, con il modulo 4 firmato il 23 giugno 2025. Non sono stati coinvolti titoli derivati in questa operazione.

La presentación del Formulario 4 revela que Sanam Parikh, Directora de Tharimmune (THAR), realizó una compra directa de acciones de la empresa el 20 de junio de 2025. Detalles de la transacción interna:

  • Adquirió 1,000 acciones de acciones comunes a $1.45 por acción
  • Valor total de la transacción: $1,450
  • Tras la compra, Parikh posee ahora directamente 1,770 acciones

Esta compra por parte de un miembro del consejo podría indicar confianza en las perspectivas futuras de la compañía. La transacción se reportó dentro del plazo requerido, con el Formulario 4 firmado el 23 de junio de 2025. No se involucraron valores derivados en esta operación.

Form 4 제출서에 따르면, Sanam Parikh Tharimmune(THAR) 이사가 2025년 6월 20일 회사 주식을 직접 매수한 것으로 나타났습니다. 내부자 거래 세부 사항은 다음과 같습니다:

  • 1,000주의 보통주를 주당 $1.45에 매수
  • 총 거래 금액: $1,450
  • 매수 후 Parikh 이사는 직접 1,770주를 보유하게 됨

이사회 구성원의 이러한 내부자 매수 활동은 회사의 미래 전망에 대한 신뢰를 나타낼 수 있습니다. 거래는 제출 기한 내에 보고되었으며, Form 4는 2025년 6월 23일에 서명되었습니다. 이 거래에는 파생 증권이 포함되지 않았습니다.

Le dépôt du formulaire 4 révèle que Sanam Parikh, directrice de Tharimmune (THAR), a effectué un achat direct d’actions de la société le 20 juin 2025. Détails de la transaction d’initié :

  • Acheté 1 000 actions ordinaires à 1,45 $ par action
  • Valeur totale de la transaction : 1 450 $
  • Après cet achat, Parikh détient désormais directement 1 770 actions

Cette opération d’achat par un membre du conseil d’administration pourrait indiquer une confiance dans les perspectives futures de l’entreprise. La transaction a été déclarée dans le délai requis, le formulaire 4 ayant été signé le 23 juin 2025. Aucun titre dérivé n’a été impliqué dans cette opération.

Die Einreichung des Formulars 4 zeigt, dass Sanam Parikh, Direktorin von Tharimmune (THAR), am 20. Juni 2025 einen direkten Kauf von Unternehmensaktien getätigt hat. Details der Insider-Transaktion:

  • Erworben wurden 1.000 Stammaktien zu 1,45 $ pro Aktie
  • Gesamtwert der Transaktion: 1.450 $
  • Nach dem Kauf hält Parikh nun direkt 1.770 Aktien

Diese Insider-Kaufaktivität eines Vorstandsmitglieds könnte auf Vertrauen in die zukünftigen Aussichten des Unternehmens hinweisen. Die Transaktion wurde innerhalb des vorgeschriebenen Meldefensters gemeldet, das Formular 4 wurde am 23. Juni 2025 unterzeichnet. Es waren keine Derivate an dieser Transaktion beteiligt.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Parikh Sanam

(Last) (First) (Middle)
C/O THARIMMUNE, INC.
34 SHREWSBURY AVENUE

(Street)
RED BANK NJ 07701

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Tharimmune, Inc. [ THAR ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/20/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/20/2025 P 1,000 A $1.45 1,770 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
/s/ Sanam Parikh 06/23/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many shares of THAR stock did Director Sanam Parikh purchase on June 20, 2025?

According to the Form 4 filing, Director Sanam Parikh purchased 1,000 shares of THAR common stock on June 20, 2025 at a price of $1.45 per share.

What is the total number of THAR shares owned by Sanam Parikh after the June 2025 purchase?

Following the reported transaction, Sanam Parikh directly owned 1,770 shares of Tharimmune, Inc. (THAR) common stock.

What was the purchase price per share for THAR stock in Parikh's June 2025 transaction?

The Form 4 filing shows that Director Parikh purchased the THAR shares at a price of $1.45 per share.

Does Sanam Parikh hold any derivative securities of THAR?

Based on Table II of the Form 4 filing, Sanam Parikh did not report holding or transacting in any derivative securities of THAR (such as options, warrants, or convertible securities).

What is Sanam Parikh's role at THAR?

According to the Form 4 filing, Sanam Parikh serves as a Director of Tharimmune, Inc. (THAR) and is not listed as having any other roles such as officer or 10% owner.
Tharimmune Inc

NASDAQ:THAR

THAR Rankings

THAR Latest News

THAR Latest SEC Filings

THAR Stock Data

6.47M
1.60M
1.62%
7.71%
1.88%
Biotechnology
Pharmaceutical Preparations
Link
United States
BRIDGEWATER